LCM
TLIS

Legato Capital Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Legato Capital Management’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,239
Closed -$205K – 337
2021
Q2 		$205K Buy
+1,239
New +$210K 0.03% 361

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legato Capital Management's TLIS Position: Q3 2021 in Review

Legato Capital Management sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2021, closing a stake of 1,239 shares — an estimated $205K sold.

Legato Capital Management first reported a position in TLIS in Q2 2021 and held it in 1 quarter. The position peaked at $205K in Q2 2021. 38 funds tracked by Wall St. Rank hold TLIS as of Q3 2021.

  • Legato Capital Management reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2021 after selling out during the quarter.
  • Legato Capital Management sold 1,239 Talis Biomedical Corporation Common Stock shares in Q3 2021, an estimated $205K.
  • Legato Capital Management first reported a position in Talis Biomedical Corporation Common Stock in Q2 2021 and held it in 1 quarter.
  • Legato Capital Management's Talis Biomedical Corporation Common Stock position peaked at $205K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2021.

Based on Legato Capital Management's 13F filing for Q3 2021, filed 9 Nov 2021.